Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EB-DUALNK in recurrent or refractory epithelial ovarian cancer
NCT07589543Phase 2Recruiting
- Sponsor
- Biotech Pharmaceutical
- Start
- Mar 2026
- Primary completion
- Mar 2027
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of EB-DUALNK in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC), primary peritoneal carcinoma (PPC), sponsored by Biotech Pharmaceutical. Started Mar 2026; status: recruiting.
02
Drugs
EB-DUALNK
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT07589543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07589543.